Pharmacokinetic Boosting of Olaparib to Improve Exposure, Tolerance and Cost-effectiveness (PROACTIVE)
Primary Purpose
Cancer
Status
Recruiting
Phase
Phase 4
Locations
Netherlands
Study Type
Interventional
Intervention
Olaparib
Cobicistat
Sponsored by

About this trial
This is an interventional treatment trial for Cancer focused on measuring olaparib, pharmacokinetic enhancement
Eligibility Criteria
Inclusion Criteria:
- Subjects who are able and willing to provide written informed consent prior to screening;
- Age of 18 years or older;
- Able to measure the outcome of the study in this subject.
Part A:
- Subjects who start or are on treatment with olaparib tablets 300mg twice daily, according to the drug label and physician's discretion;
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
Part B:
- Subjects who start on treatment with olaparib tablets 300mg twice daily, according to the drug label and physician's discretion;
- Expected to be on olaparib treatment for ≥ 3 months;
- ECOG performance status of 0-3.
Exclusion Criteria:
- Concurrent use of other anti-cancer therapies;
- Concurrent use of potent inducers or inhibitors of the cytochrome p450 enzyme 3A3 (CYP3A4) as assessed with the Dutch drug database "G-Standaard" of the Royal Dutch Pharmacists Association(KNMP);
- Known contra-indications for treatment with cobicistat in line with the summary of product characteristics;
- Subjects with renal insufficiency defined as estimated glomerular filtration rate < 50 ml/min.
Sites / Locations
- Netherlands Cancer Institute-Antoni van LeeuwenhoekRecruiting
- RadboudumcRecruiting
- ErasmusMCRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Standard olaparib
Boosted olaparib
Arm Description
Olaparib 300mg twice daily
Olaparib 100mg twice daily + cobicistat 150mg twice daily
Outcomes
Primary Outcome Measures
Part A: Olaparib AUC0-12h
The Area-Under-the-Curve (AUC) 0-12h of olaparib.
Part B: Progression-free survival (PFS)
PFS is defined as time from randomization until the date of either objective radiological disease progression, or biochemical progression combined with clinical progression or death.
Part B: Dose reductions
Number of patients who require a dose reduction due to toxicity.
Secondary Outcome Measures
Part A: Inter- and intrapatient variability of AUC0-12h
Inter- and intrapatient variability of AUC0-12h in olaparib as calculated with non-compartmental analysis.
Part A: Adverse events
Number of patients with treatment-related adverse events as assessed by CTCAE v5.0.
Part B: Health status
Health status as assessed with the EuroQol 5 dimensions with 5 levels questionnaire (EQ-5D-5L).
Part B: Patient satisfaction
Patient satisfaction as assessed with the Cancer Therapy Satisfaction Questionnaire (CTSQ).
Part B: ctDNA
Cell-free tumor nucleic acids (ctDNA) in plasma as pharmacodynamic biomarker.
Part B: Adverse events
Number of patients with treatment-related adverse events as assessed by CTCAE v5.0.
Part B: Productivity costs
Productivity costs as assessed by the iMTA Productivity Costs Questionnaire (iPCQ).
Part B: Medical consumption
Medical consumption as assessed by the iMTA Medical Consumption Questionnaire (iMCQ).
Full Information
NCT ID
NCT05078671
First Posted
September 22, 2021
Last Updated
October 21, 2022
Sponsor
Radboud University Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT05078671
Brief Title
Pharmacokinetic Boosting of Olaparib to Improve Exposure, Tolerance and Cost-effectiveness
Acronym
PROACTIVE
Official Title
Pharmacokinetic Boosting of Olaparib to Improve Exposure, Tolerance and Cost-effectiveness
Study Type
Interventional
2. Study Status
Record Verification Date
September 2022
Overall Recruitment Status
Recruiting
Study Start Date
December 15, 2021 (Actual)
Primary Completion Date
December 31, 2025 (Anticipated)
Study Completion Date
December 31, 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Radboud University Medical Center
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Olaparib is a poly-adenosine diphosphate ribose polymerase (PARP) inhibitor, originally used for the maintenance treatment of women with platinum-sensitive relapsed breast cancer gene (BRCA)-mutated high grade serious epithelial ovarian, fallopian tube, or peritoneal cancer, who are in response to platinum-based chemotherapy. Over the last two years, several therapeutic indications have been added to the drug label, such as first-line platinum-sensitive BRCA-mutated high grade serious epithelial ovarian, fallopian tube, or peritoneal cancer, germline BRCA1/2-mutated, human epidermal growth factor 2 (HER2-)negative, locally advanced or metastatic breast cancer and BRCA1/2-mutated metastatic castration-resistant prostate cancer, who have progressed following prior therapy. Since olaparib is very expensive, this increase of treatment population will have a significant impact on health care expenditures.
To keep healthcare affordable and accessible for all patients, innovative strategies are warranted to reduce the dose of expensive drugs, without reduction of efficacy. For olaparib, pharmacokinetic (PK) boosting can be applied. PK boosting is the lay term for administering a non-therapeutic active strong inhibitor of a metabolic enzyme, for example the cytochrome p450 enzyme 3A (CYP3A), together with a therapeutic drug that is metabolized by the same enzyme. Boosting thus increases the concentration of the therapeutic drug and allows lower doses to be administered to patients. Hence, coadministration of a reduced dose of olaparib with cobicistat, a non-therapeutic, strong inhibitor of the CYP3A can lead to equivalent exposure to olaparib. Furthermore, inhibition of CYP3A could lead to less PK variability since metabolic capacity is a prominent cause for (intra- and inter-individual) variability in systemic exposure. Predictable olaparib exposure will reduce the number of patients who are unintentionally under- or overtreated. Lastly, tumor tissue itself may express CYP3A as a detoxification or resistance mechanism. Theoretically, PK boosting may also overcome CYP3A-mediated drug resistance.
The purpose of this study is to establish the efficacy, safety and feasibility of co-administering olaparib with the PK booster cobicistat with the aim to implement boosting approach for olaparib in routine practice. The study is subdivided in two parts. In part A of the study the equivalent exposure of boosted low dose olaparib is determined compared to the normal dose. In part B of the study, non-inferiority of the boosted olaparib regimen will be confirmed.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cancer
Keywords
olaparib, pharmacokinetic enhancement
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
Part A: cross-over normal olaparib versus boosted olaparib. Part B: normal olaparib versus boosted olaparib in two patient groups.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
160 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Standard olaparib
Arm Type
Active Comparator
Arm Description
Olaparib 300mg twice daily
Arm Title
Boosted olaparib
Arm Type
Experimental
Arm Description
Olaparib 100mg twice daily + cobicistat 150mg twice daily
Intervention Type
Drug
Intervention Name(s)
Olaparib
Intervention Description
olaparib treatment
Intervention Type
Drug
Intervention Name(s)
Cobicistat
Intervention Description
Pharmacokinetic booster
Primary Outcome Measure Information:
Title
Part A: Olaparib AUC0-12h
Description
The Area-Under-the-Curve (AUC) 0-12h of olaparib.
Time Frame
2 weeks
Title
Part B: Progression-free survival (PFS)
Description
PFS is defined as time from randomization until the date of either objective radiological disease progression, or biochemical progression combined with clinical progression or death.
Time Frame
12 months
Title
Part B: Dose reductions
Description
Number of patients who require a dose reduction due to toxicity.
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Part A: Inter- and intrapatient variability of AUC0-12h
Description
Inter- and intrapatient variability of AUC0-12h in olaparib as calculated with non-compartmental analysis.
Time Frame
2 weeks
Title
Part A: Adverse events
Description
Number of patients with treatment-related adverse events as assessed by CTCAE v5.0.
Time Frame
2 weeks
Title
Part B: Health status
Description
Health status as assessed with the EuroQol 5 dimensions with 5 levels questionnaire (EQ-5D-5L).
Time Frame
12 months
Title
Part B: Patient satisfaction
Description
Patient satisfaction as assessed with the Cancer Therapy Satisfaction Questionnaire (CTSQ).
Time Frame
12 months
Title
Part B: ctDNA
Description
Cell-free tumor nucleic acids (ctDNA) in plasma as pharmacodynamic biomarker.
Time Frame
12 weeks
Title
Part B: Adverse events
Description
Number of patients with treatment-related adverse events as assessed by CTCAE v5.0.
Time Frame
12 months
Title
Part B: Productivity costs
Description
Productivity costs as assessed by the iMTA Productivity Costs Questionnaire (iPCQ).
Time Frame
From date of randomization until the date of end-of-treatment, assessed up to 12 months
Title
Part B: Medical consumption
Description
Medical consumption as assessed by the iMTA Medical Consumption Questionnaire (iMCQ).
Time Frame
From date of randomization until the date of end-of-treatment, assessed up to 12 months
Other Pre-specified Outcome Measures:
Title
Part A: Patient preference
Description
Treatment preference on a 7-point Likert scale.
Time Frame
2 weeks
Title
Part B: Intratumoral olaparib
Description
Intratumoral olaparib concentration in tumor biopsy samples.
Time Frame
At 8 weeks after start treatment and at the moment of progression
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subjects who are able and willing to provide written informed consent prior to screening;
Age of 18 years or older;
Able to measure the outcome of the study in this subject.
Part A:
Subjects who start or are on treatment with olaparib tablets 300mg twice daily, according to the drug label and physician's discretion;
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
Part B:
Subjects who start on treatment with olaparib tablets 300mg twice daily, according to the drug label and physician's discretion;
Expected to be on olaparib treatment for ≥ 3 months;
ECOG performance status of 0-3.
Exclusion Criteria:
Concurrent use of other anti-cancer therapies;
Concurrent use of potent inducers or inhibitors of the cytochrome p450 enzyme 3A3 (CYP3A4) as assessed with the Dutch drug database "G-Standaard" of the Royal Dutch Pharmacists Association(KNMP);
Known contra-indications for treatment with cobicistat in line with the summary of product characteristics;
Subjects with renal insufficiency defined as estimated glomerular filtration rate < 50 ml/min.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Joanneke K Overbeek, PharmD
Phone
+31-24-3617744
Email
joanneke.overbeek@radboudumc.nl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nielka van Erp, prof. PharmD PhD
Organizational Affiliation
Radboud University Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Netherlands Cancer Institute-Antoni van Leeuwenhoek
City
Amsterdam
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Frans Opdam, MD, PharmD, PhD
Facility Name
Radboudumc
City
Nijmegen
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nielka van Erp, prof. PharmD PhD
Facility Name
ErasmusMC
City
Rotterdam
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ron H.J. Mathijssen, prof. MD, PhD
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Pharmacokinetic Boosting of Olaparib to Improve Exposure, Tolerance and Cost-effectiveness
We'll reach out to this number within 24 hrs